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Balloon angioplasty fails to provide acceptable long-term results for a significant proportion of patients. An
intravascular mechanical support, developed with the aim of preventing restenosis and acute closure of dis-
eased arteries after transluminal angioplasty, was implanted in 44 patients (39 male and five female), aged
from 35 to 70 years (mean 56 years) with documented restenosis of native coronary artery (41 stents) and
bypass grafts (12 stents). In the group of bypass graft patients there was no local restenosis and no major
complication. In patients in whom stents were placed in native coronary arteries, the complication rate was
higher (two patients died after coronary bypass surgery). One patient died suddenly at home. Except for one
patient, in whom a new lesion developed proximally with extension into the stent, no case of restenosis could be
observed.
Despite the still relatively high complication rate, we feel that stenting may present a rational approach to
the unresolved problem of restenosis after coronary angioplasty.
Introduction
Restenosis after transluminal coronary angio-
plasty (PTCA) remains an unresolved problem.
About one third'11 of all patients will return within
the first three months after PTCA for a second or
third procedure thus reducing the benefit of an
otherwise elegant and comparatively inexpensive
procedure.
Despite significant improvements in coronary
angioplasty equipment, the basic mechanism of
PTCA has not changed in the 10 years of its exis-
tence. Therefore, it is not surprising that the rate
of restenosis has remained relatively constant over
many years. Modifications of procedural factors,
such as balloon size, inflation presence, and number
and duration of inflations, have failed to enhance
the long-term results; in addition, drugs like cal-
cium antagonists, platelets inhibitors, steroids and
anticoagulants have not proved to induce restenosis
rate12'. We have therefore investigated whether a
mechanical intraluminal support implanted im-
mediately after PTCA may provide a solution to the
problem of restenosis.
Methods
A self-expanding, tubular stent prosthesis con-
sisting of a woven stainless-steel mesh (Fig. 1) was
developed in collaboration with Medinvent SA,
Lausanne. The stent can be constrained on a angio-
plasty-like delivery catheter the outer diameter of
which does not exceed 1-5 mm. The delivery cath-
eter is advanced over a long exchange wire which
remains in situ after the preceding angioplasty, and
the retaining doubled-over membrane is then pro-
gressively withdrawn, thus deploying the stent in its
unconstrained state at the site of the dilated lesion'31.
Patient selection
Patients were enrolled in the study between April
and July 1986; there were 39 male and 5 female
patients, with ages ranging from 35 to 70 years
(mean 56 years). All patients showed restenosis
after previous PTCA; most patients had undergone
two or three dilatations of the offending lesion
before stent implantation and the interval between
previous PTCA and re-dilatation with stenting
averaged 9 weeks. All patients had objective and
subjective signs of myocardial ischaemia according
to history and a stress electrocardiogram. Informed
consent (as per Helsinki declaration) was obtained
from each patient and the study was approved by
the Hospital Ethics Committee.
Study protocol
In view of the potential problems and hazards
associated with intracoronary stents we preferred
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(a)
Figure I The stainless steel, multi-filament, self-expanding, macropor-
ous prosthesis during use: (a) mounted on the debvery catheter, (b) fully
expanded in the unconstrained state.
to consider our initial experience as an open study
and, therefore, a control group was not used. The
indication for stent implantation was posed by two
cardiologists and one cardiovascular surgeon. The
following were considered to be contraindications:
lesions longer than 20 mm, stenoses immediately
adjacent to the left main bifurcation or to the origin
of a large diagonal or marginal branch, impossi-
bility of adequate follow-up, and intolerance to the
concomitant drug treatment.
Patients were given 1 g of aspirin on the day prior
to the procedure. One hour before cardiac cath-
eterization they received 10 mg of diazepam p.o.
together with 10 mg of nifedipine p.o. Before bal-
loon dilatation, 10 000-15 000 units of heparin
were injected through the arterial catheter; the last
15 patients also received 0-2 mg intracoronary
nifedipine. Heparin (5000 units) was added if the
procedure lasted more than 90 min. Balloon angio-
plasty was carried out using standard equipment.
After the last balloon inflation, a 300 cm long wire
(0014in) was inserted and flushed with small
amounts of urokinase during the exchange process.
The stent delivery catheter was advanced over the
exchange guide wire until it had passed the freshly
dilated lesion. The correct position of the con-
strained stent was assured by multiple injections of
contrast before and during the deployment in order
to allow for last-minute adjustment. In three cases
the lesion was not ideally covered by one single
stent: a second stent was implanted proximally
overlapping the first by 1-2 mm.
Intracoronary nitrates were only administered if
there was evidence of spasm following the stent
deployment. After the procedure, the patients were
observed in the intensive care unit and a heparin
drip was started; partial thromboplastin time (PTT)
was maintained for 70-90 s. All patients received
oral anticoagulants (acenocoumarin) for three
months in addition to their antiplatelet regimen; the
latter consisted of aspirin (330 mg) plus dipyrida-
mol (75 mg) three times per day or, more recently,
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aspirin (lOOmg) plus dipyridamol (400 mg) and
sulfinpyrazon (400 mg) in two divided doses per day
following a suggestion by Fuster141. Prevention of
vasospasm was also pursued for three months by
adding 20 mg of nifedipine three times per day. The
patients were discharged from the hospital once
oral anticoagulation was stable, and were closely
followed by frequent examination. Stress tests were
performed after six weeks and three months, and
control coronary angiography was scheduled 3—6
months after implantation; four patients had a
second control coronary angiogram after one year.
Results
Among all patients who received intracoronary
stents, 44 were treated for restenosis. A total of 53
stents were implanted in 49 sessions. Of these, 24
stents were implanted in the left anterior descend-
ing coronary artery (LAD), one of which was
implanted in the first diagonal branch. Only one
patient in this group had a double stent placed in the
proximal LAD. Thirteen stents were implanted in
the right coronary artery including two consecutive
stents in the same vessel. Four single stents were
placed in the circumflex coronary artery. Twelve
stents were implanted in bypass grafts; two patients
had three stents placed in the same bypass graft (one
in two sessions and one in three sessions) and one
patient had two stents placed in different bypass
grafts during the same session.
The first follow-up angiogram 24 h after the pro-
cedure showed patency in all but one patient. In this
particular patient the offending vessel was a left
anterior coronary artery which perfused a partially
infarcted region. There was evidence of collateral
flow, but, because the patient was symptomatic
with angina class II, it was decided to dilate the
proximal 90% lesion which had restenosed after
previous angioplasty. The stent was placed without
difficulties; the immediate post-operative angio-
gram, however, revealed evidence of thrombotic
material within the stent lumen. At that time, it was
not customary to redilate the stent after placement
with the angioplasty balloon. The stent was found
to be occluded at the time of coronary angiography
the next morning. It was decided not to recanalize
the occlusion.
One early occlusion occurred three days after a
placement following a maximal stress test. The stent
was recanalized and remained open for some time
but was found to be reclosed at the four-months
follow-up. In addition, one patient had a suspected
occlusion (also after maximal stress test) three days
after implantation; this patient was operated on for
an internal mammary artery bypass graft. At the
time of operation no evidence of a thrombosis could
be found. The case of this patient has been reported
elsewhere131. One patient with a long lesion (23 mm)
of the proximal left anterior descending coronary
artery, in the presence of a highly stenosed bypass
graft to the same artery, underwent angioplasty and
stenting with excellent immediate result. The stent
was placed with its proximal end very close to the
bifurcation to the circumflex artery without, how-
ever, interfering with it. The patient was asympto-
matic for almost three months; he then developed
angina again and was found to have a high-grade
stenosis of the left main coronary artery extending
into the stent. It was decided to submit this patient
to his third elective bypass operation from which he
did not recover, due to surgical complications. One
patient with restenosis at the junction of a vein graft
to the left anterior descending coronary artery
(LAD) had a myocardial infarct due to occlusion
of the distal vessel three months after the stent
implantation. One patient with two stents in the
proximal left anterior descending coronary artery
died suddenly at home; it turned out that he had
refused to take the prescribed medication after
hospital discharge. Unfortunately no autopsy could
be performed.
All other patients had an uneventful clinical
course without evidence of restenosis. Follow-up
coronary angiography showed some local thicken-
ing in most patients; the degree of this proliferation,
however, never reached the level of significant
obstruction (Figs 2 and 3). The overall local thick-
ening was estimated to be a 10% reduction in the
percentage diameter stenosis.
In recent patients, followed for an interval of less
than three months (Fig. 4) and in whom no control
angiography was performed, the exercise ECG was
used to judge the results of the procedure. These
patients also did not show any evidence of resteno-
sis. A few patients had a thallium myocardial scinti-
graphy with normal flow pattern.
Among the complications encountered were
local spasms immediately after the stent placement;
these spasms, in general, responded to the local
administration of isosorbite dinitrate or calcium
antagonists. Spasm has not been a major problem
since we introduced an intracoronary injection of
nifedipine before the stent deployment. Important
arrhythmias necessitating electrical defibrillation
occurred three times during the placement. These
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Figure 2 Restenosis of a dominant right coronary artery, (a) Three
months after primary transluminal angioplasty in a 52 year old patient, (b)
Immediately after angioplasty and implantation of a stent of 4 mm maxi-
mal diameter and 23 mm length; the stent is visible without contrast injec-
tion in the left part of the picture, (c) Three months after the stent implant
there is no evidence of reduction of luminal diameter.
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Figure 3 Complicated high grade stenosis of a bypass graft to the right coronary artery in a 51 year old
patient, (a) Before stent implantation, (b) The stent of 4-5 mm maximal diameter and 20 mm length in place;
opacification with contrast medium renders the stent invisible, (c) Three months after stent implantation.
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Figure 4 Histogram of the duration of the clinical and angiographic follow-up after
stent implantation for restenosis. The hatched segments of the columns represent the
angiographic follow-up; the open segments of the columns correspond to a clinical
follow-up with ergometry and/or thallium scintigraphy.
arrhythmias are probably due to prolonged ischae-
mia. Among the most frequent complications was
local haematoma, requiring surgical revision in two
cases.
Discussion
The statistical likelihood of restenosis occurring
after angioplasty, even when dealing with the
second or third procedure at the same site, is quite
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high. The fact that we have not observed restenosis
within a stented segment (except for one patient in
whom a new stenosis was noted proximal to the
stent extending into the stent) probably indicates
that stenting may reduce the incidence of restenosis.
The absence of a control group, however, does not
permit us to draw any firm conclusion, although it
would be extremely unlikely for none of the here-
described patients not to develop restenosis after
the angioplasty procedure without stenting.
Several factors may be responsible for the occur-
rence of restenosis: platelet adhesion or thrombus
formation, localized proliferation of smooth muscle
cells, and accelerated lipid uptake at the site of
pressure induced intimal damage15"71.
Several techniques aim to improve the primary
angioplasty results by smoothing the internal vas-
cular surface or by preventing thrombosis and
tissue ingrowth into the lumen after balloon dila-
tation or, ideally, both. The concept of improving
the primary results of PTCA could be advantageous
for a number of reasons: internal fissures and
cracks, dissection and flaps cause blood turbulence,
stasis and thrombosis, which may then be organized
into restenosis. Also turbulent blood flow may ac-
celerate the deposition of atherosclerotic material
possibly through suction effects on the superficial
endothelial layers. Therefore, a 'smoothing pro-
cedure' that irons out the most annoying clefts and
dissections resulting from transluminal angioplasty
might be the solution to a great deal of problems
secondary to a highly traumatic assault on the
arterial wall. The laser balloon'81 which, according
to preliminary observation, has the capacity to
heat-sealing dissections and surface cracks may
provide such an approach within the near future
without the need for prosthetic material.
Prevention of tissue ingrowth requires either a
growth barrier or suppression of the nutritional
blood supply to the cellular substrate. Interstitial
cell proliferation within the different layers of the
arterial wall may also play a role in the genesis of
stenosis; this mechanism could, theoretically, also
be treated by interventions designed to impede
nutritional flow via the vasa vasorum. Whether
elastic recoil or spasm'9101 of the arterial wall plays a
role in the occurrence of restenosis has never been
substantiated. It seems conceivable, however, that a
combination of these different mechanisms may be
responsible for many cases of clinical restenosis
after angioplasty. Prevention of restenosis should,
therefore, deal with each of these possible modes of
action.
We conclude that elastic intravascular stents
may: (1) optimize the initial result of PTCA by
smoothing the rugged, traumatized endothelial sur-
face; (2) prevent elastic recoil and contraction of the
arterial wall; and (3) possibly suppress nutritional
flow to the cell layers that potentially form the sub-
strate for cell proliferation. Whether the stent itself
presents a significant barrier for cell proliferation
seems doubtful, because the pores between the wire
mesh have deliberately been chosen to be much
larger than the metal surface in order to enhance
rapid endothelialization. Nevertheless, the fibrous
neo-endothelium may finally become a kind of
physiological fence for cellular ingrowth.
Our clinical observations of up to 17 months in
patients with previous documented restenosis after
coronary angioplasty or deterioration of saphenous
vein bypass grafts seem to corroborate these specu-
lations. Transluminal dilatation of bypass grafts is
known to yield acceptable long-term results in only
half of the cases; 50% or more develop recurrence at
the site of the previous lesion within the first three
months. In our series of 12 bypass grafts stents, we
observed no restenosis within the stented segment.
The interpretation of data obtained from patients
in whom the native coronary artery was stented to
prevent restenosis is somewhat more complex for
two reasons: first, the rate of restenosis is generally
lower, and secondly we have seen one case in which
coronary artery restenosis developed within three
months upstream to the stent but extending into the
stented segment. In addition, the overall compli-
cation rate is higher in this patient group.
Nevertheless, we are encouraged by these prelimi-
nary observations on the prevention of restenosis
after coronary angioplasty. It must not be over-
looked, however, that the price to pay for this
achievement is still high, as reflected by the compli-
cation rate, the longer hospital stay, the higher
morbidity, and the necessity of anticoagulant treat-
ment. Improvements are necessary, not only in
respect to the stent delivery technology, but also to
diminish thrombogenicity and spasmogenicity of
intracoronary stents.
References
[1] Meier B, King III SB, GruentzigARe/a/. Repeat coron-
ary angioplasty. J Am Coll Cardiol 1984; 4: 463-80.
[2] Meier B. Restenosis after coronary angioplasty: review
of the literature. Eur Heart J 1988; 9(Suppl Q : 1-6.
[3] Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger
L. Intravascular stents to prevent occlusion and resteno-
sis after transluminal angioplasty. New Eng] J Med
1987; 316: 701-6.
Prevention of coronary restenosis by stenting 37
[4] FusterV. Personal communication, 1987.
[5] Essed CE, Van den Brand M, Becker AE. Transluminal
coronary angioplasty and early restenosis — fibrocellu-
lar occlusion after wall alteration. Br Heart J 1983; 49:
393.
[6] Waller WF, Rothbaum DA, Gorfinkel HJ, Ulbright
TH, Linnemeier TJ, Berger SM. Morphologic obser-
vations after percutaneous transluminal balloon angio-
plasty of early and late aortocoronary saphenous vein
bypass grafts. J Am Coll Cardiol 1984; 4: 784.
[7] Faxon DP, Sanbom TA. Restenosis following translu-
minal angioplasty in experimental atherosclerosis.
Arteriosclerosis 1984; 4: 189.
[8] Jenkins RD, Sinclair IN, Anand R, Spears JR. Laser
balloon angioplasty: thermal profile for in vitro welding
of neointimal arterial separations. J Am Coll Cardiol
1987; 9(2): 105A.
[9] Hollman J, Austin GE, Gruentzig AR, Douglas JS Jr,
King SB III. Coronary artery spasm at the site of angio-
plasty in the first 2 months after successful percutaneous
transluminal coronary angioplasty. J Am Coll Cardiol
1983; 2: 1039-45.
[10] Probst P, Zangl W, Baumgartner C, Pachinger 0. The
inducibility of coronary artery spasm after successful
PTCA. Eur Heart J 1988; 9(Suppl C): 19-20.
